(Original title: 60,000 shareholders, don't make a mistake. Important tips after the demon stock market is in a row! The exchange's soul tortures, is it deliberately pulling stock prices? (The closing price hit a new low during the year, and 6 shares were undervalued)

Jiu'an Medical Jiulian Board is newly added to become a demon stock. The stock price hit a new low during the year, and the valuation of 6 shares reached a record low at the same time.

After the Jiu'an Board, Jiu'an Medical indicated that production capacity ≠ actual production

Yesterday evening, Jiu'an Medical issued a change announcement. The company “painstakingly” drew shareholders' attention to investment risks, reiterated that the overseas sales revenue of the relevant kit was affected by many factors. Currently, it is not possible to predict the impact of this product on revenue and performance. Furthermore, it was clarified that previous interaction could not be equated with actual production and sales volume. The company reminds investors not to make false inferences due to conceptual confusion.

This is the fourth time that the company has recently disclosed a stock price change announcement. Although the company's change announcement was made soft, it still cannot stop investors' enthusiasm for buying. As of the latest, Jiu'an Medical has been rising and stopped for 9 consecutive days.

The surge in Jiu'an Medical began as early as November 8, and this is closely related to a company announcement on the evening of November 7. Jiu'an Medical announced that the subsidiary's household COVID-19 self-test kit has obtained emergency use authorization (EUA) from the US Food and Drug Administration (FDA) and can be sold in the US and countries/regions that recognize the US EUA. Three trading days after this announcement, market performance was mediocre.

From November 11 to 15, Jiu'an Medical frequently responded to investors' questions during interactive sessions, saying “production will increase to 200 million servings per month in early 2022,” “household self-test kits are popular in the US,” “monthly production capacity is 100 million servings,” “the price of a COVID-19 antigen home self-test OTC kit is 6.99 US dollars (1 serving),” etc.

According to the company's response, some investors calculated that Jiu'an Medical's monthly sales in the US could reach 700 million US dollars or even 1.4 billion US dollars. The annual sales amount is even more frightening. Such impressive performance simply cannot match the market value of just over 3 billion dollars (before continuous ups and downs).

Since then, the company's stock price has been as listed. Since November 15, Jiu'an Medical has taken nine rises and stops. Since November, it has increased by 166.33%, ranking first on the main board. Or because of this “monthly production capacity of 100 million people” response, the market value of Jiu'an Medical directly soared by nearly 4.5 billion yuan in the past 9 trading days. According to data disclosed by Jiu'an Medical on November 19, more than 60,000 investors held this stock, with an average household profit of more than 75,000 yuan.

The sharp change in Jiu'an Medical's stock price naturally attracted the attention of the exchange. On November 23, Jiu'an Medical received a letter of concern from the Shenzhen Stock Exchange requesting clarification on whether responses to kit products on the interactive platform were prudent and objective, and whether there were any misleading statements or statements of a promotional, advertising, or exaggerated nature.

At the same time, some investors questioned the company's failure to release important information in a timely manner. On the interactive platform, some investors asked questions. On November 6, your company had already received news that the US authorized your company to produce a self-test OTC test kit for COVID-19 antigen use in the US. Why did you delay announcing this important news to the public until November 15?

Jiu'an Medical said that due to various factors such as the unpredictability of the development of the epidemic, the promotion of vaccination plans, the validity period of the product emergency use authorization (EUA), and market development and changes, the company is currently unable to predict the future impact of this product on the company's revenue and performance.

Judging from the post-market Dragon Tiger list, all of the capital involved in the speculation was from the sales department, including Huatai Zhejiang Branch, Jiefang North Road, Shaoxing, Zhejiang, and Huaxin Shanghai Branch.

It is worth noting that Jiu'an Medical introduced several stock option incentive plans in 2020. The first exercise period began on October 25, 2021, and the exercise price was 11.53 yuan/copy. After a sharp rise in this round, Jiu'an Medical's latest stock price of 16 yuan has exceeded the exercise price by nearly 40%. Before the sharp rise, the company's stock price was only over 6 yuan, far lower than the exercise price.

The total number of incentive recipients who met the conditions for exercise during the first exercise period was 187, including senior executives such as the deputy general manager, financial director, and director secretary. The number of actionable options was 3,047 million.

There are doubts about whether the company will derail its stock price by releasing benefits after the exercise period. In the letter of concern, the Shenzhen Stock Exchange asked very directly, asking the company to explain whether there is a situation where it is suspected that incentive recipients of the 2020 Stock Options Incentive Plan can exercise their rights independently to profit by boosting stock prices. Regarding this spiritual torture, the Shenzhen Stock Exchange requested that it be disclosed to the public by November 26. However, as of the latest, listed companies have yet to respond to the above situation.

The closing price of 35 shares was the lowest in the year, with a retracement of up to 70%

As the end of the year approaches, along with the rapid rotation of the sector, the stock prices of some listed companies have broken out of the highest during the year, and there are also companies whose stock prices have hit new lows during the year or have driven to their lowest point in recent years.

The fundamentals of these companies with low stock prices are not too poor, nor is it bad news. According to the Securities Times · Databao statistics, excluding IPOs listed this year, in the past 10 trading days (November 12 to November 25), there were only 35 companies with the lowest closing price during the year. Of these, 15 had the lowest closing price of the year this week.

Judging from the industry distribution, these 35 stocks are mainly distributed in the chemical, pharmaceutical, biological, and computer industries. The market value of 8 stocks is less than 10 billion yuan, and the market value of 7 companies exceeds 100 billion yuan. Most of them are industry leaders, such as Hikvision, China China Free, and Zhifei Biotech.

The lowest closing prices of the year in the past three trading days include Pan-Micro Network, Yutong Bus, Suning Tesco, and China China Free. As the largest duty-free shop leader in China, China China Duty Free's closing price on November 25 was 211.8 yuan. Dragged down by falling short of performance and other reasons, the company's stock price has fluctuated and declined since it hit a record high in mid-February.

Hikvision's closing price on November 23 was the lowest in the year. The company is the largest supplier of security video surveillance products in China, and its main capital and leveraged capital have recently flowed out frequently.

Looking at the comparison between the highest price and the lowest closing price during the year, the 35 stocks mentioned above retracted by an average of 43%, the proportion of individual stocks that withdrew more than 30% was nearly 80%, there were as many as 10 companies with 50% or more, and the 3 shares of Jiakai City, Xuedai Education, and Blue Light Development withdrew more than 65%. The highest price in Jiakai City on February 26 this year was the highest during the year, reaching 9.14 yuan. The closing price on November 22 was 2.34 yuan, and the pullback was close to 75%. The 7 100 billion market capitalization stocks retracted by an average of 41.4%. Sany Heavy Industries, Rongsheng Petrochemical, and China Central Free had the biggest pullback. The top 2 stocks exceeded 50%, and China's China Central Free Company was close to being cut short.

Normally, when the stock price is close to a low level, there will be greater resistance to decline. Under the capital game in line with a good development trend, when valuations are also relatively low, there may be potential for an increase. Data Bank statistics show that out of the 35 stocks mentioned above, only 6 had the lowest valuation of the year this week, namely China CITIC Bank, Pan-Micro Network, Hikvision, Chenguang Stationery, China China Exemption, and General Healthcare. Those with valuations below 30 times were China CITIC Bank and Hikvision. Hikvision's valuation was less than 29 times, and the highest valuation during the year was over 50 times.

Judging from institutional forecast data, the six companies mentioned above have all received institutional forecast performance growth. The net profit growth rate of China China Free and Tongce Medical is expected to continue to exceed 30% from 2021 to 2023, China CITIC Bank's performance growth rate will remain within 10%, and Hikvision's net profit growth is expected to continue to exceed 20% from 2021 to 2022.

Disclaimer: All of Databao's information does not constitute investment advice. The stock market is risky, and investment should be cautious.